Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia
NCT ID: NCT04352569
Last Updated: 2024-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
44 participants
INTERVENTIONAL
2016-05-03
2026-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To assess the efficacy of tDCS on auditory hallucinations, the investigators performs an randomized double blind versus placebo trial. In each arms patients will receive two tDCS sessions a day during two weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Direct Current Stimulation and Effects on Early Auditory Processing in Schizophrenia
NCT03537703
tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia
NCT05440955
Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
NCT01963676
Efficacy of tACS for Treatment of Auditory Hallucinations in Refractory Schizophrenia
NCT05282329
TDCS for Auditory Hallucinations in Schizophrenia
NCT01898299
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main study purpose is to evaluate the effectiveness of tDCS on resistant auditory hallucinations in patients with schizophrenia.
Then, to evaluate the effectiveness of tDCS on global schizophrenic symptomatology and to assess the impact of tDCS on patients' quality of life.
Also the study, evaluate the impact of tDCS on cortical excitability. We measure the change in serum BDNF (Brain Derived Neutrophic Factor) before and after tDCS stimulation. Indeed, to evaluate the impact of tDCS on neurocognitive functions.
Patients will receive either active tDCS or placebo tDCS randomly. All patients will have two tDCS/day sessions, one hour apart, for 2 working weeks. The stimulation parameters will be consistent with the literature data, namely: Intensity = 2mA; duration of sessions = 20 minutes; total number of sessions = 20 (2 daily sessions for two working weeks).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
transcranial direct current stimulation
The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the LTP, le cathode over L DLPFG.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
transcranial direct current stimulation sham
tDCS device allows sham stimulation. This technic give the same impression that active stimulation and allows optimum placebo stimulation.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Refractory auditory hallucinations(despite two antipsychotics trials).
* Right-handed patients.
* Written informed consent.
Exclusion Criteria
* History of severe head trauma or coma.
* History of epilepsy or neurological disorder or a general medical condition.
* Presence of intracranial metallic objects or pacemaker.
* Hospitalized patients without consent.
* pregnant women .
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre hospitalier de Ville-Evrard, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noomane Bouaziz, MD
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NOOMANE BOUAZIZ, MD
Role: PRINCIPAL_INVESTIGATOR
Unité de Recherche Clinique de l'EPS de Ville Evard
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
unité de recherche clinique de l'E.P.S de Ville Evrard
Neuilly-sur-Marne, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMDPT-TCH/MM/2015-A00842-47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.